CNSP

Company Overview — What Does CNS Pharmaceuticals, Inc. Do?

CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, an anthracycline that is in Phase I and II clinical trials that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc. and The University of Texas M.D. Anderson Cancer Center, as well as Animal Life Sciences, LLC; and a development agreement with WPD Pharmaceuticals Inc., as well as a collaboration agreement with Reata Pharmaceuticals, Inc. The company was incorporated in 2017 and is based in Houston, Texas. CNS Pharmaceuticals, Inc. (CNSP) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO John M. Climaco and employs approximately 5 people. With a market capitalization of $1M, CNSP is one of the notable companies in the Healthcare sector.

CNS Pharmaceuticals, Inc. (CNSP) Stock Rating — Avoid (April 2026)

As of April 2026, CNS Pharmaceuticals, Inc. receives a Avoid rating with a composite score of 18.6/100 and 1 out of 5 stars from the Blank Capital Research quantitative model.CNSP ranks #4,401 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, CNS Pharmaceuticals, Inc. ranks #824 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

CNSP Stock Price and 52-Week Range

CNS Pharmaceuticals, Inc. (CNSP) currently trades at $2.18. The stock gained $0.05 (2.3%) in the most recent trading session. The 52-week high for CNSP is $10.59, which means the stock is currently trading -79.4% from its annual peak. The 52-week low is $0.66, putting the stock 230.6% above its annual trough. Recent trading volume was 11K shares, suggesting relatively thin trading activity.

Is CNSP Overvalued or Undervalued? — Valuation Analysis

CNS Pharmaceuticals, Inc. (CNSP) carries a value factor score of 6/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 0.30x, versus the sector average of 2.75x.

At current multiples, CNS Pharmaceuticals, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

CNS Pharmaceuticals, Inc. Profitability — ROE, Margins, and Quality Score

CNS Pharmaceuticals, Inc. (CNSP) earns a quality factor score of 11/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -342.7%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -179.8% versus the sector average of -33.1%.

Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

CNSP Debt, Balance Sheet, and Financial Health

CNS Pharmaceuticals, Inc. has a debt-to-equity ratio of 91.0%, compared to the Healthcare sector average of 32.0%. Leverage is within a manageable range for the industry, though investors should monitor debt trends over time. The current ratio is 1.98x, suggesting adequate working capital coverage. Total debt on the balance sheet is $30,793. Cash and equivalents stand at $10M.

CNSP has a beta of 1.04, meaning it is roughly in line with the broader market in terms of price volatility. The stability factor score for CNS Pharmaceuticals, Inc. is 18/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

CNS Pharmaceuticals, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, CNS Pharmaceuticals, Inc. reported revenue of $0 and earnings per share (EPS) of $-35.75. Net income for the quarter was $-16M. Operating income came in at $-16M.

In FY 2025, CNS Pharmaceuticals, Inc. reported revenue of $0 and earnings per share (EPS) of $-35.75. Net income for the quarter was $-16M. Operating income came in at $-16M.

In Q3 2025, CNS Pharmaceuticals, Inc. reported revenue of $0 and earnings per share (EPS) of $-5.76. Net income for the quarter was $-3M. Operating income came in at $-3M.

In Q2 2025, CNS Pharmaceuticals, Inc. reported revenue of $0 and earnings per share (EPS) of $-6.42. Net income for the quarter was $-2M. Operating income came in at $-2M.

Over the past 8 quarters, CNS Pharmaceuticals, Inc. has experienced revenue contraction from $0 to $0. Investors analyzing CNSP stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

CNSP Dividend Yield and Income Analysis

CNS Pharmaceuticals, Inc. (CNSP) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

CNSP Momentum and Technical Analysis Profile

CNS Pharmaceuticals, Inc. (CNSP) has a momentum factor score of 18/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 56/100 reflects moderate short selling activity.

CNSP vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, CNS Pharmaceuticals, Inc. (CNSP) ranks #824 out of 838 stocks based on the Blank Capital composite score. This places CNSP in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing CNSP against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full CNSP vs S&P 500 (SPY) comparison to assess how CNS Pharmaceuticals, Inc. stacks up against the broader market across all factor dimensions.

CNSP Next Earnings Date

No upcoming earnings date has been announced for CNS Pharmaceuticals, Inc. (CNSP) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy CNSP? — Investment Thesis Summary

The quantitative profile for CNS Pharmaceuticals, Inc. suggests caution. The quality score of 11/100 flags below-average profitability. The value score of 6/100 indicates premium valuation. Momentum is weak at 18/100, a headwind for near-term performance. High volatility (stability score 18/100) increases portfolio risk.

In summary, CNS Pharmaceuticals, Inc. (CNSP) earns a Avoid rating with a composite score of 18.6/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on CNSP stock.

Related Resources for CNSP Investors

Explore more research and tools: CNSP vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare CNSP head-to-head with peers: CNSP vs AZN, CNSP vs SLGL, CNSP vs VMD.